Sort
4,870 grants matching “glp 1”
Enhancement of Conditional Reprogramming Technology for Production of Functional Human Beta-Cells
$225,000Brian Andrew Pollok · Propagenix, Inc. · R43 · FY2017 · DK
Treatment of Neuroblastoma by Inhibition of Sphingosine Kinase
$225,000Charles D Smith · Apogee Biotechnology Corporation · R43 · FY2019 · CA
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
$225,000Srinivas Sridhar · Theranano, Llc · R41 · FY2017 · CA
Targeting Therapeutics for Accelerated Bone Fracture Repair
$225,000Stewart Andrew Low · Novosteo, Inc. · R44 · FY2018 · DE
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease
$225,000Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2015 · AG
Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification
$225,000Krishna Kumar · Veraquel Technologies, Inc. · R41 · FY2014 · DK
A Novel Immunotolerizing Therapy for Autoimmune Vitiligo
$225,000Andrew L Salzman · Radikal Therapeutics, Inc. · R43 · FY2014 · AR
Development of DT-109 as an oral therapeutic for type 2 diabetes
$225,000Zhongmin Alex Ma · Diapin Therapeutics, Llc · R43 · FY2015 · DK
Orally available transition state inhibitors for triple negative breast cancer
$225,000Steven Isaacman · Nanometics, Llc · R41 · FY2014 · CA
Directed Antifungal Therapy for HIV-associated Cryptococcal Meningitis
$224,976Aaron Richard McCabe · Minnetronix, Inc. · R41 · FY2015 · AI
Directed Chemotherapy Delivery for Leptomeningeal Metastases
$224,970Aaron Richard McCabe · Minnetronix, Inc. · R41 · FY2016 · CA
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases
$224,946Xiuling Lu · Nami Therapeutics Corp. · R41 · FY2019 · CA
Development of a Novel Therapeutic Approach for Cryptococcal Meningitis
$224,917Aaron Richard McCabe · Minnetronix, Inc. · R41 · FY2015 · AI
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
$224,879Joshua Canzoneri · Adt Pharmaceuticals, Llc · R43 · FY2015 · CA
STING-Activating GM-CSF Secreting Allogeneic Pancreas Tumor Cell Vaccine Therapy
$224,878Thomas W. Dubensky · Aduro Biotech · R43 · FY2014 · CA
A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation
$224,837David Ruppert · Deep Blue Medical Advances, Inc. · R41 · FY2017 · GM
Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems
$224,700Stephen Lebeau · Nanomag, Llc · R44 · FY2015 · DE
A Novel Peptide Therapeutic for Obesity
$224,700Neil A Fanger · Virtici, Llc · R43 · FY2014 · DK
Developing a highly specific and sensitive glucagon ELISA kit
$224,670Xiaomin Fan · Avantgen, Inc. · R43 · FY2015 · DK
Clinical Translation of Near Infrared Nerve-Specific Fluorophores for Nerve-sparing Prostatectomy
$224,658Connor William Barth · Inherent Targeting, Llc · R44 · FY2021 · CA
Regulation of Food Intake and Body Weight by GLP-1
$224,589Roger Reidelberger · Creighton University · R01 · FY2007 · DK
Targeting Synaptotagmin-2 to Prevent Airway Mucus Obstruction
$224,576Burton F Dickey · Exotect, Llc · R41 · FY2017 · HL
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$224,486Jerzy Szewczyk · Biokier, Inc. · R44 · FY2015 · DK
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis
$224,482Peter B Heifetz · Orpro Therapeutics, Inc. · R44 · FY2018 · HL
Ph2.Study of PAT-001 for Treatment of Congenital Ichthyosis IND122058(7/27/2016)
$224,469Zachary Rome · Patagonia Pharmaceuticals, Llc · R01 · FY2018 · FD